Despite the extensive literature on this topic, no bibliometric analysis has been performed.
To ascertain studies related to preoperative FLR augmentation techniques, the Web of Science Core Collection (WoSCC) database was scanned for publications released from 1997 up to 2022. In order to perform the analysis, CiteSpace [version 61.R6 (64-bit)] and VOSviewer [version 16.19] were employed.
A total of 973 scholarly works were produced by 4431 academics affiliated with 920 institutions situated across 51 countries/regions. Japan's remarkable productivity eclipsed all other nations, standing in contrast to the University of Zurich's leading publication count. A noteworthy amount of published articles was attributed to Eduardo de Santibanes, while Masato Nagino garnered the most co-citations across various publications. The journal with the most frequent publications was HPB, contrasting with Ann Surg, which held the top spot in citations, reaching 8088. The principal objectives of preoperative FLR augmentation include improving surgical approaches, broadening the patient base for this procedure, tackling and preventing complications after surgery, establishing sustained patient survival, and evaluating the growth patterns of FLR. Currently, among the popular search terms in this field are ALPPS, LVD, and hepatobiliary scintigraphy.
The bibliometric analysis, focusing on preoperative FLR augmentation techniques, presents a comprehensive review offering valuable insights and innovative ideas for the field.
Scholars in the field of preoperative FLR augmentation techniques will find valuable insights and ideas presented in this comprehensive bibliometric analysis.
The abnormal proliferation of cells in the lungs, a cause of lung cancer, is ultimately fatal. Chronic kidney issues, much like other widespread health problems, impact people globally, causing renal failure and negatively affecting kidney function. Among the prevalent illnesses impacting kidney function are cysts, kidney stones, and tumors. Identification of lung cancer and renal conditions, which often present without symptoms, is essential for preventing serious complications, and must be conducted early and accurately. Bionanocomposite film The use of Artificial Intelligence is essential for achieving earlier detection of dangerous diseases. Employing transfer learning from ImageNet pre-trained weights, this study proposes a modified Xception deep neural network for automatic multi-class classification of lung and kidney CT scans. Multi-class lung cancer classification using the proposed model resulted in 99.39% accuracy, 99.33% precision, 98% recall, and 98.67% F1-score. Remarkably, the kidney disease multi-class classification demonstrated an impressive 100% accuracy, F1 score, precision, and recall. Following the modification, the Xception model outperformed both the initial Xception model and the existing methods. Thus, it can offer support to radiologists and nephrologists, contributing to the early identification of lung cancer and chronic kidney disease, respectively.
Bone morphogenetic proteins (BMPs) are integral to both the initiation and the spread of tumors within cancers. Disagreement remains over the precise effects of BMPs and their antagonistic molecules in breast cancer (BC), which are influenced by the wide range of biological functions and signaling involved. A comprehensive and in-depth study of the family's signaling mechanisms in breast cancer is being investigated.
Using the TCGA-BRCA and E-MTAB-6703 cohorts, a study analyzed the aberrant expression levels of BMPs, their receptors, and antagonists within primary breast cancer tumors. The association between breast cancer and bone morphogenetic proteins (BMPs) was explored utilizing related biomarkers, encompassing estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), proliferation, invasion, angiogenesis, lymphangiogenesis, and bone metastasis.
The present study revealed a statistically significant augmentation of BMP8B in breast tumors, while a concurrent reduction was observed in BMP6 and ACVRL1 levels in the breast cancer tissues analyzed. Poor overall survival in BC patients was substantially associated with elevated levels of BMP2, BMP6, TGFBR1, and GREM1 expression. BMPs' aberrant expression, along with their receptors, was investigated across various breast cancer subtypes categorized by ER, PR, and HER2 status. Higher levels of BMP2, BMP6, and GDF5 were discovered in triple-negative breast cancer (TNBC), a finding that stands in contrast to the relatively higher presence of BMP4, GDF15, ACVR1B, ACVR2B, and BMPR1B in luminal type breast cancers. ACVR1B and BMPR1B showed a positive correlation with ER, however, a reciprocal, inverse correlation with ER was also evident. In HER2-positive breast cancer, elevated levels of GDF15, BMP4, and ACVR1B expression were associated with inferior overall patient survival outcomes. Breast cancer's tumor growth and metastasis are intertwined with the functions of BMPs.
Different breast cancer subtypes exhibited varying BMP patterns, hinting at subtype-specific involvement. Further research is warranted to elucidate the precise function of these BMPs and their receptors in disease progression and distant metastasis, specifically through their modulation of proliferation, invasion, and EMT.
A study of breast cancer subtypes revealed contrasting BMP patterns, implying subtype-specific involvement. three dimensional bioprinting Further investigation into the precise function of these BMPs and their receptors in disease progression and distant metastasis, including their regulation of proliferation, invasion, and EMT, is warranted.
Current blood-derived indicators of pancreatic adenocarcinoma (PDAC) prognosis are restricted. Gemcitabine-treated stage IV PDAC patients who experience poor prognoses are often found to exhibit SFRP1 promoter hypermethylation (phSFRP1), according to recent research. see more This study examines the consequences of phSFRP1 expression in patients with early-stage pancreatic ductal adenocarcinoma.
Employing methylation-specific PCR, the bisulfite-treated SFRP1 gene's promoter region was investigated. Kaplan-Meier curves, log-rank tests, and generalized linear regression analysis were instrumental in determining restricted mean survival time at the 12- and 24-month time points.
The study investigated 211 patients displaying pancreatic ductal adenocarcinoma, specifically stage I-II. Regarding overall survival, patients with phSFRP1 displayed a median time of 131 months, markedly different from the 196-month median observed in patients with unmethylated SFRP1 (umSFRP1). After controlling for other variables, phSFRP1 was associated with a 115-month (95% CI -211, -20) and a 271-month (95% CI -271, -45) loss of lifespan at 12 and 24 months, respectively. There was no noteworthy effect of phSFRP1 on patients' disease-free or progression-free survival trajectories. In PDAC patients at stage I-II, those exhibiting the phSFRP1 biomarker have a less positive prognosis compared to those with the umSFRP1 biomarker.
Adjuvant chemotherapy's lessened effectiveness, as indicated by the results, could be a cause of the unfavorable prognosis. Clinicians may find SFRP1 helpful in their decision-making process, and it may also be a viable target for drugs that alter epigenetic mechanisms.
Reduced efficacy from adjuvant chemotherapy might explain the poor prognosis indicated by the results. SFRP1 may serve as a useful tool for clinicians, and it is a potential target of epigenetic-modifying drugs.
Diffuse Large B-Cell Lymphoma (DLBCL)'s inherent heterogeneity presents a significant obstacle to the creation of more effective treatments. Nuclear factor-kappa B (NF-κB) frequently exhibits abnormal activation in diffuse large B-cell lymphoma (DLBCL). While transcriptionally active, NF-κB dimers, containing RelA, RelB, or cRel, are observed, the diversity in their composition among and within diverse DLBCL cell populations is currently unknown.
Employing a novel flow cytometry technique, 'NF-B fingerprinting,' we delineate its versatility in analyzing DLBCL cell lines, DLBCL core-needle biopsies, and blood samples from healthy controls. The distinct NF-κB profiles observed in each cell population demonstrate the limitations of established cell-of-origin classifications in comprehensively characterizing the NF-κB diversity in diffuse large B-cell lymphoma (DLBCL). RelA is predicted by computational models to be a primary determinant of the cellular reaction to microenvironmental factors, and experimental results show significant RelA variability between and within ABC-DLBCL cell lines. We employ computational models that incorporate NF-κB fingerprints and mutational details to predict the heterogeneous responses of DLBCL cell populations to microenvironmental stimuli, a prediction verified through experimental validation.
Our findings highlight that the diversity of NF-κB composition in DLBCL is directly correlated with the predicted response of DLBCL cells to their surrounding environment. Studies show that mutations commonly found in the NF-κB signaling pathway hinder DLBCL's ability to react to its microenvironmental surroundings. A widely applicable analysis technique, NF-κB fingerprinting, quantifies NF-κB heterogeneity within and between cell populations in B-cell malignancies, showcasing functionally important differences in NF-κB composition.
Our results highlight the significant compositional heterogeneity of NF-κB in DLBCL cells, a critical factor in predicting their responses to microenvironmental stimulation. The impact of common NF-κB pathway mutations on DLBCL's response to microenvironmental cues has been established. A widely applicable analysis tool for assessing NF-κB heterogeneity in B-cell malignancies is NF-κB fingerprinting, which demonstrates functionally important variations in NF-κB composition between and within different cell types.